This brand name is authorized in Estonia, Lithuania, Poland
The drug KROMEYA contains one active pharmaceutical ingredient (API):
|
1
Adalimumab
UNII FYS6T7F842 - ADALIMUMAB
|
|
Adalimumab binds specifically to TNF and neutralizes the biological function of TNF by blocking its interaction with the p55 and p75 cell surface TNF receptors. Adalimumab also modulates biological responses that are induced or regulated by TNF, including changes in the levels of adhesion molecules responsible for leukocyte migration (ELAM-1, VCAM-1, and ICAM-1 with an IC50 of 0.1-0.2 nM). |
This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:
| ATC code | Group title | Classification |
|---|---|---|
| L04AB04 | Adalimumab | L Antineoplastic and immunomodulating agents → L04 Immunosuppressants → L04A Immunosuppressants → L04AB Tumor necrosis factor alpha (TNF-α) inhibitors |
This drug has been assigned below unique identifiers within the countries it is being marketed:
| Country | Identification scheme | Identifier(s) |
|---|---|---|
| Country: EE | Ravimiamet | Identifier(s): 1792098, 1792100, 1792188 |
| Country: LT | Valstybinė vaistų kontrolės tarnyba | Identifier(s): 1087481, 1087482, 1087483, 1088578, 1088579 |
| Country: PL | Rejestru Produktów Leczniczych | Identifier(s): 100419049, 100419055, 100419061 |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
